Cargando…

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients

BACKGROUND: Cytomegalovirus (CMV) commonly affects solid organ transplant (SOT) recipients, with increased risks of rejection, graft failure, and other infections. While valganciclovir (vGCV) prophylaxis is effective in preventing CMV, its use is sometimes hindered by toxicity. We examined the assoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lahoud, Chloe, Franceschi, Andres E, Reyes, Fabiola, Moshovitis, Dimitrios G, Achkar, Angela, Chakraborty, Antara, Balusu, Manu, Safiia, Jawad, Nussbaum, Eliezer Zachary, Letourneau, Alyssa R, Hammond, Sarah P, Kotton, Camille N, Koo, Sophia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678726/ http://dx.doi.org/10.1093/ofid/ofad500.2326

Ejemplares similares

Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
por: Gonzalez-Bocco, Isabel H., et al.
Publicado: (2023)

845. Clinical Outcomes in Patients Treated with High vs. Standard Dose Liposomal Amphotericin B for Invasive Mucormycosis
por: Valiante, Sarah, et al.
Publicado: (2023)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation
por: Rissling, Olesja, et al.
Publicado: (2018)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

Cytokine and Chemokine Secretome and Risk of CMV Infection Following Discontinuation of Valganciclovir Prophylaxis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2023)

2719. Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study
por: Nussbaum, Eliezer Zachary, et al.
Publicado: (2023)

Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
por: Johansson, Inger, et al.
Publicado: (2013)

The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2019)

Valganciclovir: Leucopenia: case report
Publicado: (2021)

Risk factors for therapeutic ERCP-related complications: an analysis of 2,715 cases performed by a single endoscopist
por: Katsinelos, Panagiotis, et al.
Publicado: (2014)

Promoters and inhibitors for quality improvement work in general practice: a qualitative analysis of 2715 free-text replies
por: Eide, Torunn Bjerve, et al.
Publicado: (2022)

Breast cancer survival after mammography dissemination in Brazil: a population-based analysis of 2,715 cases
por: Fernandes, Juliana O., et al.
Publicado: (2023)

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease
por: Vezina, Heather E, et al.
Publicado: (2009)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients
por: shi, yiyun, et al.
Publicado: (2020)

2646. Incidence of Myelosuppression Related to Valganciclovir Prophylaxis in Solid-Organ Transplant Recipients at High Risk of CMV Disease
por: Belga, Sara, et al.
Publicado: (2019)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
por: Kabata, Yoshiaki, et al.
Publicado: (2012)

Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma
por: Stragliotto, Giuseppe, et al.
Publicado: (2020)

Mycophenolate-mofetil/valganciclovir: Neutropenia: case report
Publicado: (2022)

1703. Hematologic Toxicity of Valganciclovir Prophylaxis in Solid Organ Transplant Recipients as a Function of Weight-adjusted Ganciclovir Exposure
por: Campanella, Toni A, et al.
Publicado: (2020)

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation
por: Li, Po-Hsien, et al.
Publicado: (2021)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

2715. Pneumococcal Community-Acquired Pneumonia Attributed to PCV13 Serotypes in Hospitalized Adults: Comparison of the 50–64 and 65+ Age Groups
por: LeBlanc, Jason J, et al.
Publicado: (2019)

1571. Cost-Effectiveness Analysis of Duration of Valganciclovir Prophylaxis Among CMV Serology Mismatched (Donor+/Recipient−) Lung Transplant Recipients
por: Tomko, Heather, et al.
Publicado: (2018)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
por: Patil, A Jayaprakash, et al.
Publicado: (2010)

Development of an appropriate simple suspension method for valganciclovir medication
por: Masaoka, Yasuyuki, et al.
Publicado: (2020)

Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma
por: Pantalone, Mattia Russel, et al.
Publicado: (2022)

1564. Lower Rates of Epstein–Barr Virus (EBV) Viremia in Pediatric Solid Organ Transplant (SOT) Recipients Who Received Valganciclovir Prophylaxis
por: Moulton, Elizabeth A, et al.
Publicado: (2018)

210. Neutropenia and Associated Infectious Complications Among Kidney Transplant Recipients Receiving Valganciclovir Prophylaxis in the United States: An Administrative Claims Database Study
por: Turzhitsky, Vladimir, et al.
Publicado: (2022)

Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial
por: Reischig, Tomas, et al.
Publicado: (2018)

Chronic Human Herpes Virus 8 Infection Successfully Treated With Valganciclovir
por: Yun, James J, et al.
Publicado: (2009)

New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients
por: Åsberg, A, et al.
Publicado: (2014)

High Throughput Screening of Valganciclovir in Acidic Microenvironments of Polyester Thin Films
por: Schaller, Teilo, et al.
Publicado: (2015)

1146. Thrombocytosis in Infants with Congenital Cytomegalovirus Infection Being Treated with Valganciclovir
por: Murtagh, Kathleen, et al.
Publicado: (2020)

Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation
por: Cheyssac, Elodie, et al.
Publicado: (2023)

Role of Valganciclovir in Children with Congenital CMV Infection: A Review of the Literature
por: Pata, Davide, et al.
Publicado: (2023)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome?
por: Mozaffar, Maryam, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_075337a55jpqjeebf349iepqc2